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ABSTRACT
Objective: Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy commonly associated with psoriasis, a large number of patients with PsA 
that has persistent inflammation may develop progressive joint damage and disability and have reduced life expectancy. This study aims to determine 
the associations of anti-cyclic citrullinated peptide (CCP) antibodies in adult patients with psoriasis and PsA.
Methods: A case–control study was conducted at Baghdad teaching hospital, Units of Rheumatology and Dermatology, during the period from 
December 2016 to April 2017 including three groups; 40 patients with psoriasis, 40 patients with PsA fulfilling the CASPAR classification criteria, and 
40 healthy control persons.
Results: Two patients with psoriasis (5%) and 10 patients with PsA (25%) were seropositive for anti-CCP antibodies (ACPA). Healthy controls were 
negative for anti-CCPA. Regarding ACPA positivity, a significant difference was found between those three studied groups (p<0.001) and there was a 
significant difference between positive and negative ACPA in PsA patients regarding disease activity score (p=0.044).
Conclusion: Positive ACPA were found more significant with PsA than in patients with psoriasis as well as associated with higher disease activity.
Keywords: Psoriasis, Psoriatic arthritis, Anti-cyclic citrullinated peptide antibodies.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy 
commonly associated with psoriasis [1]. Initially, PsA was considered 
to be a mild, non-progressive disease compared with rheumatoid 
arthritis (RA). However, accumulating evidence confirms that a 
substantial proportion of patients with PsA has persistent inflammation, 
develops progressive joint damage and disability, and has reduced life 
expectancy [2].
Psoriasis associated with a lot of complications includes metabolic 
syndrome. Metabolic syndrome-induced oxidative stress may play an 
important role in the development of cognitive impairment, neuropathy, 
and depressive disorders while its effect on cell proliferation, 
angiogenesis, and apoptosis may contribute to the pathogenesis of 
colorectal cancer [3]. In addition, autonomic dysfunction may be occur 
with varying frequency and intensity, sympathetic nervous system 
dysfunction can lead to severe consequences including myocardial 
infarction, arrhythmias, and sudden cardiac death [4].
It equally affects men and women at the 3rd–5th decade of life (30–50 
years), it is more common in Caucasians and has a clear genetic 
predisposition. It has a prevalence of 0.04–0.2%, in the general 
population and 25–34%, in patients with psoriasis [5]. Most patients 
(70%) have preexisting psoriasis, but in 20% arthritis predates the 
occurrence of skin disease. Occasionally, arthritis and psoriasis develop 
synchronously [6]. Cyclic citrullinated peptide (CCP) is an artificial 
molecule in which two serine residues in a major epitope peptide from 
filaggrin is converted to cysteine, and the circular form is made by S-S 
disulfide bond [7]. Anti-CCP antibodies (ACPA) are autoantibodies 
(antibodies directed against one or more of the individuals own 
proteins) frequently detected in RA patients. During inflammation, 
citrulline is incorporated enzymatically into proteins, in a reaction 
which is called citrullination [8]. These autoantibodies are well known 
to carry a poor prognostic value in RA and because of the recently 
noticed aggressive behavior of PsA that tends to be similar to RA so we 
try to look for the factors that may cause this aggressive course.
METHODS
Study design and sample selection
A case–control study was included on 120 subjects, who attended Units 
of Rheumatology and Dermatology in Baghdad teaching hospital for 
their routine follow-up during the period from December 2016 to April 
2017. The subjects were divided into three groups; 40 patients with 
psoriasis (positive control) whom diagnosed clinically and subdivided 
into three groups according to the severity of psoriasis using psoriasis 
area and severity index (PASI) score, 40 PsA patients fulfilling the 
CASPAR classification criteria for PsA [9], and 40 apparently healthy 
controls with age and sex matched. All patients were informed of the 
objectives of the study and gave verbal consent for their voluntary 
participation in the study. Patients with overlap with other collagen 
vascular diseases, hepatitis B and C, tuberculosis, and sepsis were 
excluded from the study.
Data collection and clinical evaluation
Data were collected using the preconstructed data collection sheet, 
questionnaire included demographic, clinical, and investigation data 
of the patients. All patients were examined concerning age, gender, 
family history, disease duration, a pattern of skin and joint involvement, 
hemoglobin, white blood cell count, platelet count, C-reactive protein 
(CRP), rheumatoid factor (RF), and erythrocyte sedimentation rate 
(ESR). All patients were graded according to the PASI score. Disease 
activity score (DAS) 28 was calculated using ESR for the assessment 
of PsA [10,11]. Estimation of ACPA levels by ELISA technique which 
is Immunoscan CCPlus® test kit (Euro Diagnostica, Sweden) used for 
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qualitative and semi-quantitative determination of IgG antibodies to 
CCP in human sera. The assay is used to detect antibodies in a single 
serum specimen.
Statistical analyses
Statistical analyses were done using SPSS version 23 computer software 
(Statistical Package for the Social Sciences) in association with Excel 
version 5. Descriptive statistics for categorical variables were done using 
frequency and percentages. To measure the strength of association 
between two categorical variables, the odds ratio (OR) was used. The 
statistical significance of the measured OR is assessed by a special χ2 
formula. Associations between two categorical variables were explored 
by cross-tabulation. The statistical significance of such associations 
was assessed by χ2 test of homogeneity or Fisher’s exact test (when the 
conditions for a valid Chi-square test are not met). The level of statistical 
significance was set at p<0.05. All analyzed tests were bilateral (two tailed).
RESULTS
Male gender was 70% in positive controls, 65% in healthy controls, and 
52.5% in the cases group with no significant difference between the three 
study groups (p=0.25). The mean age was 43.7 years among cases group, 
41.5 years among healthy controls, and 39.7 years in positive controls 
with no significant difference between groups (p=0.48) (Table 1).
The duration of arthropathy in cases group ranged from a few months 
to 25 years, with a mean duration of ±SD of 7.5±6.5 years. The DAS score 
of these cases ranged between 1.2 and 7.2, with a mean ± SD of 4.7±1.5 
years. In addition, polyarthritis was the most frequently observed type 
of arthritis, being reported in about 2nd–3rd of cases groups (67.5%), 
followed by oligoarthritis (17%), axial (8%), and DIP (8%) (Fig. 1).
Regarding skin pattern, plaque psoriasis was reported for all patients, 
no other skin pattern was reported. Regarding the PASI score, 78.75% 
presented with mild disease activity, 17.5% of patients presented with 
moderate disease activity, and 3.75% of patients presented with severe 
disease activity.
As shown in Table 2, none of the healthy controls had a positive ACPA. 
This rate increased to 5% among patients with psoriasis and further to 
25% among psoriatic arthropathy patients. The difference in a positive 
test between the three study groups was statistically significant. The 
presence of psoriatic skin lesions only increased the risk of having a 
positive ACPA test by 5.3 times compared to healthy controls, but the risk 
estimate failed to reach the level of statistical significance. The presence 
of arthritis in patients with psoriasis significantly increased the risk of 
positivity for ACPA by 6.3 times as compared to positive controls (patients 
with psoriasis but without arthritis) and 27.9 times as compared to 
healthy controls (persons who have neither psoriasis nor PsA) (Table 3).
The mean DAS 28 score was significantly higher (mean DAS score=5.5) 
among PsA cases with a positive ACPA compared to those with negative 
test (mean DAS score=4.5) (Table 4).
In Table 5, gender, family history of psoriasis, pattern of joint 
involvement, RF, and serum CRP were tested for possible association 
with positive ACPA. None of these explanatory variables showed an 
obvious or statistically significant association with positive ACPA.
As shown in Table 6, psoriasis disease activity measured by PASI score 
was not affected by the presence of arthritis. The mean PASI score was 
not significantly different between cases group with arthritis (6.6) and 
positive controls without arthritis (5.3).
DISCUSSION
The era for searching the associations between ACPA, psoriasis, and PsA 
was markedly increased in the last decade and illustrated interesting 
associations. In this study, 5% of patients with psoriasis had positive 
ACPA compared to healthy controls, but the risk estimate failed to 
reach the level of statistical significance (p=0.158). Similar results were 
described by Alenius et al. showed that there was 0.7% positive ACPA 
in psoriatic patients which were not significant also [12]. Another two 
studies were done by and Abdel Fattah et al. [13] and Candia et al. [14], 
they found that all patients had negative ACPA. ACPA was found positive 
in 25% among PsA patients and negative in healthy controls which were 
statistically significant (p<0.001). This is in agreement with previous 
studies such as Abdel Fattah et al., Candia et al., Inanc et al., Bogliolo 
et al., and Cruyssen et al. [13-17]. Did not find a significant difference 
between healthy persons and patients with PsA regarding the positivity 
for ACPA [18,19]. This contradiction may have been due to the small 
patients and control sizes used in their studies. This study also showed 
that PsA patients in comparison to patients with psoriasis have a positive 
ACPA with a statistically significant difference (p=0.023), which was 
agreed with a study done by Abdel Fattah et al. (p<0.001) and Candia 
et al. (p=0.01) [13,14]. On the other hand, other studies like Shibata 
Fig. 1: The relative frequency of selected types of arthritis among 
cases group (n=40). DIP: Distal interphalangeal









Female 14 (350) 12 (30) 19 (47.5)
Male 26 (65.0) 28 (70) 21 (52.5)
Total 40 (100) 40 (100) 40 (100)
Age (years) 0.48 (NS)
Range 19–73 18–74) 22–70
Mean±SD/SE 41.5±17.2/2.72 39.7±13.4/2.12 43.7±13.6/2.15
NS: Not significant, p: Probability, SD: Standard deviation, SE: Standard error
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et al. found that the difference was not significant between those two 
groups [19]. This contradiction may be due to the small size of PsA (n=16) 
and psoriasis (n=15) patients used in their study. The presence of arthritis 
in addition to psoriasis significantly increased the risk of positive ACPA 
by 6.3 times compared to psoriasis patients and 27.9 times compared 
to healthy controls. To the best of our knowledge, no studies mentioned 
this important significant risk. There were no differences between ACPA-
positive and ACPA-negative PsA patients in terms of gender, age, and 
disease duration. The lack of this association in our study is in agreement 
with the results of Popescu et al., Abdel Fattah et al., and Behrens 
et al. [13,20,21]. There were no significant differences between ACPA-
positive and ACPA-negative PsA patients in terms of CRP, RF, and ESR also, 
with an agreement to the study of Popescu et al. [20]. Regarding disease 
activity, statistically significant difference in mean of DAS 28 score (5.5) 
was found in ACPA-positive patients when compared with ACPA-negative 
patients (4.5) (p=0.044), this was in agreement with some studies such as 
Abdel Fattah et al., Bogliolo et al., Korendowych et al., Perez-Alamino et al., 
and Behren et al. [13,15,18,21,22] while another study such as Alenius 
et al. and Cruyssen et al. disagrees with us [12,17]. This contradiction 
may have its origin in the difference in genetics and race in contradicted 
studied groups. Another possible issue is their use of DAS 68 score which 
is different DAS. Another important clinical characteristic is polyarthritis 
pattern which was statistically non-significant in our study, similar 
results were described in studies done by Korendowych et al. and Behren 
et al. [18,21]. The latter was the largest study; 1996 patients with PsA were 
included in the study, of which 105 patients were ACPA positive [21]. On 
the other hand, other studies showed an association of ACPA seropositivity 
with polyarthritis [13,15,20,22,23]. This contradiction in multiple joint 
patterns may have its origin in the difference of race and genetics of the 
contradicted study groups. Other patterns of joint involvement showed 
no statistically significant association with the positive ACPA. To the best 
of our knowledge, there were no available data showed that association.
CONCLUSION
The presence of arthritis in addition to psoriasis significantly increased 
the risk of positive ACPA by 6.3 times compared to psoriasis patients. 
Regarding disease activity, a statistically significant higher mean of DAS 
28 score was found in ACPA-positive patients when compared with 
ACPA-negative patients.
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